The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...

Delving into the details, we found 12% of traders were bullish, while 75% showed bearish tendencies. Out of all the trades we ...

Eli Lilly (NYSE: LLY) is the most valuable healthcare stock in the world, with a market capitalization of nearly $700 billion ...

The Biden administration is proposing Medicare and Medicaid coverage for glucagon-like peptide 1 receptor agonist (GLP-1 RA) ...

A new Biden administration proposal could allow millions of Americans with obesity to access weight-loss drugs like Wegovy ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mohit ...

Discover the best Black Friday deals, Fort Wayne's ranking as a top retirement spot, and Walmart's pullback on diversity policies.

Amgen didn't clarify whether the average weight reduction of up to about 20% was a placebo-adjusted figure. It most likely referred to total weight loss, which means the candidate probably isn't any ...

More than seven million additional Americans could get coverage for popular drugs such as Zepbound and Wegovy under the ...